Lipid Regulating Agents

Substances that alter the metabolism of LIPIDS.
DrugDrug NameDrug Indication
DB00122CholineFor nutritional supplementation, also for treating dietary shortage or imbalance
DB00175PravastatinPravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.[T274] As well, pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease. This indication includes the reduction of risk of total mortality by reducing coronary death, myocardial infarction, undergoing myocardial revascularization procedures, stroke, and stroke/transient ischemic attack as well as to slow the progression of coronary atherosclerosis.[T274] The term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flow.[L6028] As adjunctive therapy to diet, pravastatin is used in: - Patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type IIa and IIb. - Patients with elevated serum triglycerides including type IV hyperlipidemia. - Patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with low-density lipoprotein (LDL) cholesterol higher than 190 mg/dl after diet modifications or LDL levels higher than 160 mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors.[T274] In patients that do not respond adequately to diet, pravastatin is used to treat patients with primary dysbetalipoproteinemia (type III hyperlipidemia).[T274] Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025]
DB00227LovastatinLovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.[F4661] Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.[F4661,F4664] Lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.[F4661] Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls with Heterozygous Familial Hypercholesterolemia (HeFH) who are at least one year post-menarche, 10 to 17 years of age, with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than 189 mg/dL or LDL-C remains greater than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient. Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed. Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00375ColestipolColestipol is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia (a condition that features elevated LDL-C) who do not respond adequately to diet [FDA Label, L6115, F4555]. Therapy with lipid-altering agents like colestipol should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia [FDA Label, L6115, F4555]. Treatment should begin and continue with dietary therapy [FDA Label, L6115, F4555]. In general, a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy such as that with colestipol [FDA Label, F4555]. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite coronary heart disease [FDA Label, F4555]. Although colestipol is effective in all types of hypercholesterolemia, some regional prescribing information note in particular that it is medically most appropriate in patients with Fredrickson's type II hyperlipoproteinemia [L6115]. Nevertheless, in patients with combined hypercholesterolemia and hypertriglyceridemia, although colestipol may be helpful in reducing elevated cholesterol, it is not formally indicated where hypertriglyceridemia is the abnormality of greatest concern [F4567].
DB00439CerivastatinUsed as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
DB00609EthionamideFor use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
DB00627NiacinNiacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]
DB00636ClofibrateFor Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.
DB00641SimvastatinSimvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).[F4655, F4658] This includes the treatment of primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial), mixed dyslipidemia (Fredrickson type IIb), hypertriglyceridemia (Fredrickson type IV hyperlipidemia), primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia), homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments, as well as adolescent patients with Heterozygous Familial Hypercholesterolemia (HeFH).[F4655, F4658] Simvastatin is also indicated to reduce the risk of cardiovascular morbidity and mortality including myocardial infarction, stroke, and the need for revascularization procedures. It is primarily used in patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease.[F4655, F4658] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB00930ColesevelamFor use, alone or in combination with an HMG-CoA reductase inhibitor, as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa).
DB00951IsoniazidFor the treatment of all forms of tuberculosis in which organisms are susceptible.
DB00973EzetimibeEzetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin), reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin, and to reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia) [FDA Label].
DB01034CeruleninFor use as a biochemical tool, Cerulenin is shown to cause dramatic weight loss in animals
DB01039FenofibrateFenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]
DB01076AtorvastatinAtorvastatin is approved for the treatment of several types of dyslipidemias including: - Primary hyperlipidemia and mixed dyslipidemia in adults. - Hypertriglyceridemia. - Primary dysbetalipoproteinemia. - Homozygous familial hypercholesterolemia. - Heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397] Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397] Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors, and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397] Atorvastatin can also be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB01095FluvastatinTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
DB01098RosuvastatinThe FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.[F4649] The Health Canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate. It is also indicated for the prevention of major cardiovascular events (including risk of myocardial infarction, nonfatal stroke, and coronary artery revascularization) in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.[F4652] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB01241GemfibrozilGemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
DB01393BezafibrateFor the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
DB01432CholestyramineIndicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
DB01599ProbucolUsed to lower LDL and HDL cholesterol.
DB05528MipomersenUsed in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.
DB06271SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.
DB06281TorcetrapibInvestigated for use/treatment in peripheral vascular disease and hyperlipidemia.
DB06630AnacetrapibInvestigated for use/treatment in hyperlipidemia.
DB06693MevastatinNot used therapeutically due to its many side effects.
DB06748Ginsenoside CNot Available
DB06756Glycine betaineBetaine is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: 1. cystathionine beta-synthase (CBS), 2. 5,10-methylenetetrahydrofolate reductase (MTHFR), 3. cobalamin cofactor metabolism (cbl).
DB08604TriclosanTriclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers. It is also used in health care settings in surgical scrubs and personnel hand washes.
DB08860PitavastatinPitavastatin is indicated for the treatment of adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). It is also indicated for the treatment of pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.[F4667] Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]
DB08983EtofibrateNot Available
DB09022BenfluorexNot Available
DB09055AcipimoxUsed in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).
DB09064CiprofibrateNot Available
DB11234PoliglusamNot Available
DB11358Evening primrose oilEvening primrose oil is used as part of over-the-counter dietary supplements.[L1113] It is also used for the treatment of systemic inflammatory diseases and for women's health conditions such as cyclical mastalgia. These indications do not have sufficient evidence of their effectiveness. It was used for the treatment of atopic dermatitis in the United Kingdom but it is currently withdrawn due to lack of evidence of effectiveness.[A33131]
DB11655EvacetrapibNot Available
DB11780AllicinNot Available
DB12181DalcetrapibNot Available
DB13348TiadenolNot Available
DB13441NiceritrolNot Available
DB13873Fenofibric acidFor use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). [FDA Label]
DB14038beta-SitosterolNot Available
DB13433SimfibrateNot Available
DB13849ClofibrideNot Available
DB13460RonifibrateNot Available
DB13780Aluminium clofibrateNot Available
DB00658SevelamerFor the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
DB04377MeglutolNot Available
DB00047Insulin glargineInsulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
DB01083OrlistatFor obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. Use of orlistat is pending revision due to reports of liver-related adverse events.
DB06586CetilistatInvestigated for use/treatment in obesity.
DB08407PLATENSIMYCINNot Available
DB09303EvolocumabFor the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering.
DB11936Bempedoic acidNot Available
DB12456BococizumabNot Available
DB13914VolixibatVolixibat is an investigational drug that has not been approved for use in any conditions.
DrugDrug NameTargetType
DB00122CholineCholine-phosphate cytidylyltransferase Btarget
DB00122CholineAcetylcholinesterasetarget
DB00122CholineCholine-phosphate cytidylyltransferase Atarget
DB00122CholinePhospholipase D2target
DB00122CholineCholinesterasetarget
DB00122CholinePhospholipase D1target
DB00122CholinePhosphoethanolamine/phosphocholine phosphatasetarget
DB00122CholineSolute carrier family 22 member 2transporter
DB00122CholineSolute carrier family 22 member 1transporter
DB00122CholineSolute carrier family 22 member 3transporter
DB00122CholineSolute carrier family 22 member 5transporter
DB00122CholineSolute carrier family 22 member 4transporter
DB00122CholineCholine/ethanolaminephosphotransferase 1enzyme
DB00122CholineCholine transporter-like protein 1transporter
DB00122CholineCholine transporter-like protein 4transporter
DB00122CholineCholine transporter-like protein 2transporter
DB00122CholineCholine transporter-like protein 3transporter
DB00122CholineCholine/ethanolamine kinaseenzyme
DB00122CholineCholine O-acetyltransferaseenzyme
DB00122CholineCholine kinase alphaenzyme
DB00122CholineCholine dehydrogenase, mitochondrialenzyme
DB00122CholineHigh affinity choline transporter 1transporter
DB00122CholineNeuronal acetylcholine receptor subunit alpha-7target
DB00175Pravastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00175PravastatinSolute carrier organic anion transporter family member 2B1transporter
DB00175PravastatinP-glycoprotein 1transporter
DB00175PravastatinSolute carrier organic anion transporter family member 1A2transporter
DB00175PravastatinSolute carrier family 22 member 6transporter
DB00175PravastatinSolute carrier family 22 member 8transporter
DB00175PravastatinCanalicular multispecific organic anion transporter 1transporter
DB00175PravastatinSolute carrier family 22 member 11transporter
DB00175PravastatinATP-binding cassette sub-family G member 2transporter
DB00175PravastatinSolute carrier family 22 member 7transporter
DB00175PravastatinSolute carrier organic anion transporter family member 1B1transporter
DB00175PravastatinMonocarboxylate transporter 1transporter
DB00175PravastatinBile salt export pumptransporter
DB00175PravastatinSolute carrier organic anion transporter family member 1B3transporter
DB00175PravastatinHistone deacetylase 2target
DB00227Lovastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00227LovastatinCytochrome P450 3A4enzyme
DB00227LovastatinCytochrome P450 2C8enzyme
DB00227LovastatinIntegrin alpha-Ltarget
DB00227LovastatinHistone deacetylase 2target
DB00227LovastatinSerum paraoxonase/lactonase 3enzyme
DB00227LovastatinP-glycoprotein 1transporter
DB00227LovastatinSolute carrier organic anion transporter family member 1A2transporter
DB00227LovastatinSolute carrier organic anion transporter family member 1B1transporter
DB00227LovastatinUDP-glucuronosyltransferase 1-1enzyme
DB00227LovastatinUDP-glucuronosyltransferase 1-3enzyme
DB00227LovastatinUDP-glucuronosyltransferase 2B7enzyme
DB00227LovastatinCanalicular multispecific organic anion transporter 1transporter
DB00227LovastatinBile salt export pumptransporter
DB00227LovastatinSerum albumincarrier
DB00227LovastatinCytochrome P450 2C19enzyme
DB00227LovastatinSolute carrier organic anion transporter family member 2B1transporter
DB00227LovastatinSolute carrier organic anion transporter family member 1B3transporter
DB00375ColestipolBile acidstarget
DB00439Cerivastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00439CerivastatinCytochrome P450 2C8enzyme
DB00439CerivastatinCytochrome P450 3A4enzyme
DB00439CerivastatinCytochrome P450 2D6enzyme
DB00439CerivastatinCytochrome P450 2C9enzyme
DB00439CerivastatinCytochrome P450 3A5enzyme
DB00439CerivastatinCytochrome P450 3A7enzyme
DB00439CerivastatinP-glycoprotein 1transporter
DB00439CerivastatinCanalicular multispecific organic anion transporter 1transporter
DB00439CerivastatinATP-binding cassette sub-family G member 2transporter
DB00439CerivastatinSolute carrier organic anion transporter family member 1B1transporter
DB00439CerivastatinCytochrome P450 2B6enzyme
DB00439CerivastatinUDP-glucuronosyltransferase 1-1enzyme
DB00439CerivastatinBile salt export pumptransporter
DB00609EthionamideCatalase-peroxidasetarget
DB00609EthionamideEnoyl-[acyl-carrier-protein] reductase [NADH]target
DB00627NiacinHydroxycarboxylic acid receptor 2target
DB00627NiacinNicotinamide N-methyltransferasetarget
DB00627NiacinNicotinate-nucleotide pyrophosphorylase [carboxylating]target
DB00627NiacinHydroxycarboxylic acid receptor 3target
DB00627NiacinSolute carrier family 22 member 5transporter
DB00627NiacinSolute carrier organic anion transporter family member 2B1transporter
DB00627NiacinMonocarboxylate transporter 1transporter
DB00627NiacinCytochrome P450 2D6enzyme
DB00627NiacinSodium-coupled monocarboxylate transporter 1transporter
DB00627NiacinMonocarboxylate transporter 4transporter
DB00627NiacinThyroxine-binding globulincarrier
DB00627NiacinCytochrome P450 3A4enzyme
DB00627NiacinCytochrome P450 2E1enzyme
DB00636ClofibratePeroxisome proliferator-activated receptor alphatarget
DB00636ClofibrateCytochrome P450 3A4enzyme
DB00636ClofibrateGlutathione S-transferase A2enzyme
DB00636ClofibrateCytochrome P450 2E1enzyme
DB00636ClofibrateCytochrome P450 1A1enzyme
DB00636ClofibrateCytochrome P450 4A11enzyme
DB00636ClofibrateThyroxine-binding globulincarrier
DB00641Simvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00641SimvastatinCytochrome P450 3A4enzyme
DB00641SimvastatinCytochrome P450 2C8enzyme
DB00641SimvastatinCytochrome P450 2C9enzyme
DB00641SimvastatinCytochrome P450 3A5enzyme
DB00641SimvastatinP-glycoprotein 1transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1A2transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1B1transporter
DB00641SimvastatinCytochrome P450 2B6enzyme
DB00641SimvastatinCytochrome P450 2D6enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-1enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-3enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 2B7enzyme
DB00641SimvastatinCanalicular multispecific organic anion transporter 1transporter
DB00641SimvastatinIntegrin alpha-Ltarget
DB00641SimvastatinBile salt export pumptransporter
DB00641SimvastatinCytochrome P450 2C19enzyme
DB00641SimvastatinSolute carrier organic anion transporter family member 2B1transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1B3transporter
DB00641SimvastatinHistone deacetylase 2target
DB00930ColesevelamBile acidstarget
DB00951IsoniazidCatalase-peroxidasetarget
DB00951IsoniazidEnoyl-[acyl-carrier-protein] reductase [NADH]target
DB00951IsoniazidCytochrome P450 2E1enzyme
DB00951IsoniazidCytochrome P450 1A2enzyme
DB00951IsoniazidCytochrome P450 2C9enzyme
DB00951IsoniazidCytochrome P450 2D6enzyme
DB00951IsoniazidCytochrome P450 2C19enzyme
DB00951IsoniazidCytochrome P450 3A4enzyme
DB00951IsoniazidArylamine N-acetyltransferase 2enzyme
DB00951IsoniazidArylamine N-acetyltransferaseenzyme
DB00951IsoniazidCytochrome P450 2A6enzyme
DB00951IsoniazidCytochrome P450 2C8enzyme
DB00951IsoniazidCytochrome P450 2C8target
DB00951IsoniazidCytochrome P450 1A2target
DB00951IsoniazidCytochrome P450 3A4target
DB00951IsoniazidCytochrome P450 2C19target
DB00951IsoniazidDihydrofolate reductasetarget
DB00951IsoniazidSerum albumincarrier
DB00973EzetimibeNiemann-Pick C1-like protein 1target
DB00973EzetimibeAminopeptidase Ntarget
DB00973EzetimibeSterol O-acyltransferase 1target
DB00973EzetimibeUDP-glucuronosyltransferase 1-1enzyme
DB00973EzetimibeUDP-glucuronosyltransferase 1-3enzyme
DB00973EzetimibeP-glycoprotein 1transporter
DB00973EzetimibeCanalicular multispecific organic anion transporter 1transporter
DB00973EzetimibeSolute carrier organic anion transporter family member 1B1transporter
DB00973EzetimibeUDP-glucuronosyltransferase 2B15enzyme
DB00973EzetimibeUDP-glucuronosyltransferase 2B7enzyme
DB00973EzetimibeCytochrome P450 3A4enzyme
DB00973EzetimibeATP-binding cassette sub-family G member 5transporter
DB00973EzetimibeCanalicular multispecific organic anion transporter 2transporter
DB00973EzetimibeATP-binding cassette sub-family G member 2transporter
DB00973EzetimibeATP-binding cassette sub-family G member 8transporter
DB00973EzetimibeCytochrome P450 2C8enzyme
DB00973EzetimibeBile salt export pumptransporter
DB01034Cerulenin3-oxoacyl-[acyl-carrier-protein] synthase 3target
DB01034Cerulenin3-oxoacyl-[acyl-carrier-protein] synthase 2target
DB01034Cerulenin3-oxoacyl-[acyl-carrier-protein] synthase 1target
DB01034CeruleninFatty acid synthasetarget
DB01039FenofibratePeroxisome proliferator-activated receptor alphatarget
DB01039FenofibrateMatrix metalloproteinase-25target
DB01039FenofibrateCytochrome P450 2C8enzyme
DB01039FenofibrateCytochrome P450 2C9enzyme
DB01039FenofibrateNuclear receptor subfamily 1 group I member 2target
DB01039FenofibrateUDP-glucuronosyltransferase 1-9enzyme
DB01039FenofibrateBile salt export pumptransporter
DB01039FenofibrateSerum albumincarrier
DB01039FenofibrateCytochrome P450 2C19enzyme
DB01039FenofibrateCytochrome P450 2A6enzyme
DB01039FenofibrateLiver carboxylesterase 1enzyme
DB01039FenofibrateCarbonyl reductase [NADPH] 1enzyme
DB01039FenofibrateAldo-keto reductase family 1 member C1enzyme
DB01039FenofibrateAldo-keto reductase family 1 member C2enzyme
DB01039FenofibrateAldo-keto reductase family 1 member C3enzyme
DB01039FenofibrateAldose reductaseenzyme
DB01076Atorvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01076AtorvastatinCytochrome P450 3A4enzyme
DB01076AtorvastatinDipeptidyl peptidase 4target
DB01076AtorvastatinCytochrome P450 2D6enzyme
DB01076AtorvastatinCytochrome P450 2C9enzyme
DB01076AtorvastatinCytochrome P450 2C19enzyme
DB01076AtorvastatinCytochrome P450 3A5enzyme
DB01076AtorvastatinCytochrome P450 3A7enzyme
DB01076AtorvastatinP-glycoprotein 1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01076AtorvastatinMultidrug resistance-associated protein 4transporter
DB01076AtorvastatinMultidrug resistance-associated protein 5transporter
DB01076AtorvastatinMultidrug resistance-associated protein 1transporter
DB01076AtorvastatinCytochrome P450 2B6enzyme
DB01076AtorvastatinCytochrome P450 2C8enzyme
DB01076AtorvastatinAryl hydrocarbon receptortarget
DB01076AtorvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01076AtorvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01076AtorvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01076AtorvastatinCanalicular multispecific organic anion transporter 1transporter
DB01076AtorvastatinBile salt export pumptransporter
DB01076AtorvastatinSerum albumincarrier
DB01076AtorvastatinHistone deacetylase 2target
DB01076AtorvastatinNuclear receptor subfamily 1 group I member 3target
DB01095Fluvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01095FluvastatinCytochrome P450 2C9enzyme
DB01095FluvastatinCytochrome P450 3A4enzyme
DB01095FluvastatinCytochrome P450 2C8enzyme
DB01095FluvastatinCytochrome P450 2D6enzyme
DB01095FluvastatinCytochrome P450 2C19enzyme
DB01095FluvastatinCytochrome P450 1A1enzyme
DB01095FluvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01095FluvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01095FluvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01095FluvastatinSolute carrier family 15 member 1transporter
DB01095FluvastatinCytochrome P450 3A5enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01095FluvastatinUDP-glucuronosyltransferase 2B7enzyme
DB01095FluvastatinCanalicular multispecific organic anion transporter 1transporter
DB01095FluvastatinCytochrome P450 2B6enzyme
DB01095FluvastatinHistone deacetylase 2target
DB01098Rosuvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01098RosuvastatinCytochrome P450 2C9enzyme
DB01098RosuvastatinMultidrug resistance-associated protein 4transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01098RosuvastatinCystine/glutamate transportertransporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01098RosuvastatinBile salt export pumptransporter
DB01098RosuvastatinATP-binding cassette sub-family G member 2transporter
DB01098RosuvastatinSerum albumincarrier
DB01098RosuvastatinCanalicular multispecific organic anion transporter 1transporter
DB01098RosuvastatinSolute carrier family 22 member 8transporter
DB01098RosuvastatinSodium/bile acid cotransportertransporter
DB01098RosuvastatinIntegrin alpha-Ltarget
DB01241GemfibrozilPeroxisome proliferator-activated receptor alphatarget
DB01241GemfibrozilCytochrome P450 2C9enzyme
DB01241GemfibrozilCytochrome P450 2C8enzyme
DB01241GemfibrozilCytochrome P450 1A2enzyme
DB01241GemfibrozilCytochrome P450 2C19enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 1-1enzyme
DB01241GemfibrozilCytochrome P450 3A4enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 1-3enzyme
DB01241GemfibrozilSolute carrier organic anion transporter family member 1B1target
DB01241GemfibrozilUDP-glucuronosyltransferase 2B7enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 1-9enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 2B4enzyme
DB01241GemfibrozilUDP-glucuronosyltransferase 2B17enzyme
DB01241GemfibrozilSerum albumincarrier
DB01241GemfibrozilSolute carrier family 22 member 8target
DB01241GemfibrozilSolute carrier organic anion transporter family member 2B1target
DB01241GemfibrozilSolute carrier organic anion transporter family member 1B3target
DB01393BezafibratePeroxisome proliferator-activated receptor alphatarget
DB01393BezafibrateSolute carrier organic anion transporter family member 1B1transporter
DB01393BezafibratePeroxisome proliferator-activated receptor deltatarget
DB01393BezafibratePeroxisome proliferator-activated receptor gammatarget
DB01393BezafibrateCytochrome P450 1A1enzyme
DB01393BezafibrateCytochrome P450 2C8enzyme
DB01393BezafibrateCytochrome P450 3A4enzyme
DB01393BezafibrateNuclear receptor subfamily 1 group I member 2target
DB01393BezafibrateRetinoic acid receptor RXR-alphatarget
DB01393BezafibrateRetinoic acid receptor RXR-betatarget
DB01393BezafibrateRetinoic acid receptor RXR-gammatarget
DB01432CholestyramineBile acidstarget
DB01599ProbucolATP-binding cassette sub-family A member 1target
DB01599ProbucolLiver carboxylesterase 1target
DB05528MipomersenmRNA of ApoB-100target
DB06271SulodexideHeparin cofactor 2target
DB06271SulodexideAntithrombin-IIItarget
DB06281TorcetrapibCholesteryl ester transfer proteintarget
DB06281TorcetrapibCytochrome P450 11B2, mitochondrialenzyme
DB06693Mevastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB06693MevastatinLiver carboxylesterase 1enzyme
DB06756Glycine betaineCholinesteraseenzyme
DB06756Glycine betaineProline dehydrogenase 1, mitochondrialenzyme
DB06756Glycine betaineApoptosis regulator Bcl-2target
DB08604TriclosanEnoyl-[acyl-carrier-protein] reductase [NADH] FabItarget
DB08604TriclosanEnoyl-[acyl-carrier-protein] reductase [NADH]target
DB08604TriclosanEnoyl-[acyl-carrier-protein] reductase [NADH] FabItarget
DB08604TriclosanEnoyl-[acyl-carrier-protein] reductase [NADH]target
DB08604TriclosanEnoyl-[acyl-carrier-protein] reductase [NADPH] FabItarget
DB08604TriclosanNuclear receptor subfamily 1 group I member 2target
DB08604TriclosanAndrogen receptortarget
DB08604TriclosanNuclear receptor subfamily 1 group I member 3target
DB08604TriclosanPeroxisome proliferator-activated receptor gammatarget
DB08604TriclosanThyroid peroxidasetarget
DB08860PitavastatinSolute carrier organic anion transporter family member 1B1transporter
DB08860PitavastatinSolute carrier organic anion transporter family member 1B3transporter
DB08860PitavastatinUDP-glucuronosyltransferase 2B7enzyme
DB08860PitavastatinUDP-glucuronosyltransferase 1-3enzyme
DB08860PitavastatinCytochrome P450 2C9enzyme
DB08860PitavastatinCytochrome P450 2C8enzyme
DB08860Pitavastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB08860PitavastatinSolute carrier organic anion transporter family member 2B1transporter
DB08860PitavastatinSodium/bile acid cotransportertransporter
DB08860PitavastatinATP-binding cassette sub-family G member 2transporter
DB08860PitavastatinP-glycoprotein 1transporter
DB08860PitavastatinCanalicular multispecific organic anion transporter 1transporter
DB08860PitavastatinSerum albumincarrier
DB08860PitavastatinAlpha-1-acid glycoprotein 1carrier
DB08860PitavastatinBile salt export pumptransporter
DB08860PitavastatinIntegrin alpha-Ltarget
DB09064CiprofibratePeroxisome proliferator-activated receptor alphatarget
DB11358Evening primrose oilElongation of very long chain fatty acids protein 5enzyme
DB11358Evening primrose oilFatty acid desaturase 1enzyme
DB11358Evening primrose oilFatty acid desaturase 2enzyme
DB13873Fenofibric acidPeroxisome proliferator-activated receptor alphatarget
DB13873Fenofibric acidMatrix metalloproteinase-25target
DB13873Fenofibric acidPeroxisome proliferator-activated receptor gammatarget
DB13873Fenofibric acidPeroxisome proliferator-activated receptor deltatarget
DB13873Fenofibric acidNuclear receptor subfamily 1 group I member 2target
DB00658SevelamerPhosphatetarget
DB04377Meglutol3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00047Insulin glargineInsulin receptortarget
DB00047Insulin glargineInsulin-like growth factor 1 receptortarget
DB00047Insulin glargineCytochrome P450 1A2enzyme
DB01083OrlistatPancreatic triacylglycerol lipasetarget
DB01083OrlistatFatty acid synthasetarget
DB01083OrlistatGastric triacylglycerol lipasetarget
DB01083OrlistatCytochrome P450 3A4enzyme
DB01083OrlistatCytosolic phospholipase A2enzyme
DB06586CetilistatPancreatic triacylglycerol lipasetarget
DB08407PLATENSIMYCIN3-oxoacyl-[acyl-carrier-protein] synthase 2target
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB13914VolixibatIleal sodium/bile acid cotransportertarget